Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Intellia Therapeutics (NTLA) Return on Equity (2016 - 2025)

Intellia Therapeutics (NTLA) has disclosed Return on Equity for 10 consecutive years, with 0.58% as the latest value for Q4 2025.

  • Quarterly Return on Equity fell 5.0% to 0.58% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 0.58% through Dec 2025, down 5.0% year-over-year, with the annual reading at 0.53% for FY2025, 3.0% down from the prior year.
  • Return on Equity for Q4 2025 was 0.58% at Intellia Therapeutics, up from 0.61% in the prior quarter.
  • The five-year high for Return on Equity was 0.25% in Q4 2021, with the low at 0.63% in Q2 2025.
  • Average Return on Equity over 5 years is 0.44%, with a median of 0.44% recorded in 2022.
  • The sharpest move saw Return on Equity grew 15bps in 2021, then fell -21bps in 2022.
  • Over 5 years, Return on Equity stood at 0.25% in 2021, then tumbled by -76bps to 0.44% in 2022, then decreased by -2bps to 0.45% in 2023, then fell by -19bps to 0.53% in 2024, then decreased by -9bps to 0.58% in 2025.
  • According to Business Quant data, Return on Equity over the past three periods came in at 0.58%, 0.61%, and 0.63% for Q4 2025, Q3 2025, and Q2 2025 respectively.